Expanding Investment and Overseas Cooperation Opportunities
IR Sessions for 9 Bio Companies and Expert Seminars Held

The Korea Technology Finance Corporation is collaborating with Seoul National University Hospital and Shinhan Financial Group to support the global expansion of domestic bio venture companies.


On June 26 (local time), the Korea Technology Finance Corporation announced on June 29 that it had jointly hosted the 'K-Bio Global Innovation Forum' in San Diego, California, USA, with Seoul National University Hospital and Shinhan Financial Group, and signed a business agreement for the 'Joint Discovery and Nurturing of Global K-Bio Venture Companies.'


On the 26th (local time), the Korea Technology Finance Corporation jointly held the "K-Bio Global Innovation Forum" in San Diego, California, USA, together with Seoul National University Hospital and Shinhan Financial Group, and signed a "business agreement for the joint discovery and cultivation of global K-Bio venture companies." In the second row, from the left, the sixth person is Hosik Jang, Head of Shinhan Bank CIB Group; Seonggeun Kwon, Vice Director of Research at Seoul National University Hospital; and Changho Cheon, Director of Korea Technology Finance Corporation, posing for a commemorative photo with other forum attendees. Photo by Kibo

On the 26th (local time), the Korea Technology Finance Corporation jointly held the "K-Bio Global Innovation Forum" in San Diego, California, USA, together with Seoul National University Hospital and Shinhan Financial Group, and signed a "business agreement for the joint discovery and cultivation of global K-Bio venture companies." In the second row, from the left, the sixth person is Hosik Jang, Head of Shinhan Bank CIB Group; Seonggeun Kwon, Vice Director of Research at Seoul National University Hospital; and Changho Cheon, Director of Korea Technology Finance Corporation, posing for a commemorative photo with other forum attendees. Photo by Kibo

View original image

On this day, the Korea Technology Finance Corporation, Seoul National University Hospital, and Shinhan Financial Group signed a business agreement and established a foundation for cooperation to foster innovative companies in the bio sector. Under the agreement, each institution plans to jointly promote the following: ▲ joint discovery and nurturing of promising bio venture companies, ▲ collaboration on technology commercialization and clinical linkages, ▲ connection of financial support such as guarantees, loans, and investments, and ▲ consulting and global network support for entry into overseas markets.


The jointly held forum was scheduled to coincide with 'BIO USA,' the world's largest bio exhibition, and focused on expanding opportunities for domestic bio venture companies to attract investment and foster overseas cooperation. About 100 people attended the forum, including domestic bio venture companies, global pharmaceutical firms, local investors (VCs), and bio industry experts.


During the forum, nine domestic bio companies seeking to enter the U.S. market participated in an investment briefing (IR), introducing their technological capabilities and business strategies to global investors and representatives from pharmaceutical companies. The subsequent expert seminar covered the latest trends and market outlook of the U.S. bio industry, as well as strategies for global expansion. In the panel discussion, various opinions were shared on topics such as attracting investments, technology transfer, and ways to revitalize the M&A market.


At the expert seminar, Professor Lee Jinhyung of Stanford University School of Medicine, a world-renowned neuroscientist, gave a special lecture on 'Enhancing Brain Health Through Innovative Solutions.' Professor Lee introduced his research and commercialization experience based on the convergence of artificial intelligence (AI) and neuroscience. In a special session linked to Stanford University's Biodesign education program, a bio-innovation methodology was presented, focusing on identifying innovative ideas from real-world medical challenges and connecting them to commercialization.



Changho Chun, Director of Korea Technology Finance Corporation, said, "Through this forum and business agreement, we have established a foundation for domestic bio venture companies to directly collaborate with overseas investors, pharmaceutical companies, and medical institutions. Korea Technology Finance Corporation will continue to actively support K-Bio companies in strengthening their competitiveness and entering global markets by leveraging our global network."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing